top of page
< Back

Vandetanib

凡德他尼

Mechanism of action:

Vandetanib 是一種多重酪胺酸激酶抑制劑(multi-target tyrosine kinase inhibitor)。多數甲狀腺髓質癌(medullary thyroid cancer)帶有 RET 原癌基因活化突變,vandetanib 可抑制 RET 激酶自我磷酸化(autophosphorylation),阻斷下游訊號,如 MAPK、PI3K/Akt,進而抑制腫瘤細胞增殖與存活。Vandetanib 也能抑制血管內皮生長因子受體 VEGFR-2,降低腫瘤新生血管形成,減少腫瘤血液供應。

​Reference(s):

1. Bates D et al. (2003). ZD-6474. AstraZeneca. Curr Opin Investig Drugs. 


2. Ton GN et al. (2013). Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm.

bottom of page